The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Disclosure of Conflicts of Interest – Prof. Stefan Symeonides

This is a disclosure report regarding direct/indirect conflicts of interest of a financial, functional or any other nature related to commercial and non-commercial organizations.

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature:

  • Scientific Advisory Boards (my institution, no personal gain): Duke Street Bio, Eisai, Ellipses, Grey Wolf Therapeutics, MSD, Roche
  • Independent Safety/Data Monitoring Boards (*honorarium): Exscientia/Recursion*, WCG/Valley Hospital*, University of Oxford, Institute of Cancer Research / Royal Marsden Hospital
  • Speaker (honorarium): Ipsen
  • Research Funding (my institution, no personal gain): MSD, Verastem
  • Clinical trials as PI/CI (my institution, no personal gain): Agalimmune/BioLineRx, AZ, BioNTech, Boston Pharmaceuticals, Corbus, Genentech, Grey Wolf Therapeutics, GSK, Incyte, Medannex, MSD, Nouscom, Nucana, Nuvectis, Pfizer, Roche, Salubris, Sapience, Scancell

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

  • University of Edinburgh – Employment
  • Cancer Research UK – Employment

 

Last updated on 28th May 2025

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70